| 000 | 01660 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515090453.0 | ||
| 264 | 0 | _c20071221 | |
| 008 | 200712s 0 0 eng d | ||
| 022 | _a1349-7006 | ||
| 024 | 7 |
_a10.1111/j.1349-7006.2007.00624.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKawaguchi, Wakae | |
| 245 | 0 | 0 |
_aSimultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. _h[electronic resource] |
| 260 |
_bCancer science _cDec 2007 |
||
| 300 |
_a2002-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdenocarcinoma |
| 650 | 0 | 4 |
_aAnnexin A5 _xanalysis |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMitogen-Activated Protein Kinase Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPaclitaxel _xtherapeutic use |
| 650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
| 700 | 1 | _aItamochi, Hiroaki | |
| 700 | 1 | _aKigawa, Junzo | |
| 700 | 1 | _aKanamori, Yasunobu | |
| 700 | 1 | _aOishi, Tetsuro | |
| 700 | 1 | _aShimada, Muneaki | |
| 700 | 1 | _aSato, Sinya | |
| 700 | 1 | _aShimogai, Ruri | |
| 700 | 1 | _aSato, Seiya | |
| 700 | 1 | _aTerakawa, Naoki | |
| 773 | 0 |
_tCancer science _gvol. 98 _gno. 12 _gp. 2002-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1349-7006.2007.00624.x _zAvailable from publisher's website |
| 999 |
_c17422561 _d17422561 |
||